|The following article is part of conference coverage from the 2018 American Academy of Dermatology Annual Meeting in San Diego, California. Dermatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in dermatology. Check back for the latest news from AAD 2018.|
A new 31-gene expression profile (GEP) test that classifies cutaneous melanoma tumors as low risk (Class 1) or high risk (Class 2) for metastasis may help inform appropriate patient management plans, according to research presented at the 2018 American Academy of Dermatology Annual Meeting, February 16-20, 2018 in San Diego, California.
In a multicenter, prospective clinical utility study, Robert Cook, PhD, and colleagues compared the pre-GEP to post-GEP management plans of 243 patients with stage I or II melanoma.
In total, 50% of patients had post-GEP changes in management, including 38% of patients with Class 1 tumors and 85% of patients with Class 2 tumors.
Overall, 80 cases had increased intensity of care, 52 cases had decreased intensity of care, and 121 cases had no change (P <.0001) following GEP testing. Of the 52 cases that had decreases in care intensity, 45 were classified as Class I, while Class 2 accounted for 51 of the 80 cases that had increases in care intensity.
GEP class was found to be a significant predictor of change in care (P <.001).
Identifying risk of metastasis using the GEP test accurately informed clinical management of patients with melanoma, including initial workup, referral patterns, and follow-up intervals.
For more coverage of AAD 2018, click here.
Cook R, et al. A prospective multicenter study to evaluate the clinical impact of a 31-gene expression profile test on physician recommendations for management of melanoma patients. Presented at: 2018 American Academy of Dermatology Annual Meeting. February 16-20, 2018; San Diego, CA. Abstract 6798.